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Background: Examining associations between viral genomic loads of enteroviruses and clinical severity is
important for promoting and improving development of antiviral drugs related to hand, foot and mouth
disease (HFMD).
Methods: Throat swabs were collected from HFMD cases at acute phase of illness using a standardized tech-
nique in a prospective study. The viral genomic load was categorized into low, medium, and high groups
using parameters of real-time reverse transcription-polymerase chain reaction. The clinical severities were
assessed with four indicators, respectively.
Findings: We analysed 1109 HFMD cases, including 538 children with CV-A6, 231 with CV-A16, 156 with EV-
A71, 78 with CV-A10, 59 with CV-A4, and 47 with CV-A2. EV-A71 genomic load categories were associated
with risks of diagnoses of CNS complications (p = 0.016), requiring systemic corticosteroids or IVIG
(p = 0.011), intensive care unit admission (p = 0.002) and length of hospital stay over 5 days (p = 0.048).
In the multivariate analyses, point estimates of adjusted odds ratio (OR) tended to increase with viral geno-
mic loads for all four severe outcomes and ORs of highest viral genomic load were all significantly larger than
one for EV-A71.
Interpretation: HFMD clinical severities positively associate with viral genomic loads of EV-A71 in throat
swabs. Specific antiviral drugs should be developed to reduce enterovirus load and to alleviate the clinical
severities for HFMD cases.
Funding: National Science Fund for Distinguished Young Scholars
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Hand, foot and mouth disease (HFMD) is an infectious disease
mostly affecting infants and children under 5 years [1]. HFMD is gen-
erally a benign self-limited disease, with most cases presenting
merely with exanthema, fever and other mild clinical manifestations,
and recovering within several days. However, in a minority of HFMD
cases, central nervous system (CNS) complications develop, which
Research in context
Evidence before this study
We searched PubMed for the articles on association between
viral load and clinical severity of hand, foot and mouth disease
(HFMD), using the search terms "hand, foot, and mouth dis-
ease", "EV71", "enterovirus 7100, "enterovirus A71", "coxsackie
virus A", "viral load", "virus load" and "genomic load" without
language restrictions. The searched articles were required to be
published from January 1, 1994 to August 30, 2020. There were
animal model studies suggesting the decrease in viral load of
EV-A71 could lead to the decline in case fatality risk, while
there was an English study reporting severe EV-A71 infections
that were related to prolonged EV-A71 viremia in patients. A
single small Chinese study compared EV-A71 viral load in 20
HFMD patients, in which no statistically significant difference
was detected between mild and severe cases.
Added value of this study
This study examined the association between enterovirus viral
load in throat swabs and clinical severity by enterovirus sero-
type among inpatient HFMD cases. We found the evidence that
the risks of developing severe HFMD was positively associated
with the viral loads of enterovirus for patients with EV-A71.
Implications of all the available evidence
Viral loads of EV-A71 were closely related to disease progres-
sion and deterioration in HFMD. Specific antiviral drugs should
be developed to reduce EV-A71 viral load. The early use of
effective antiviral drugs might improve the clinical outcome of
HFMD patients with EV-A71.
2 C. Song et al. / EBioMedicine 62 (2020) 103078may progress to cardiopulmonary collapse and death. Surviving cases
can suffer long term sequelae [1]. HFMD is caused by human entero-
viruses, which are positive-sense single stranded RNA viruses of
about 2730 nm in size [2]. The HFMD etiological agents primarily
belong to species of Enterovirus (EV) A, including commonly detected
serotypes of EV-A71, coxsackie virus (CV) A16, CV-A6 and CV-A10, as
well as other relatively rare serotypes including CV-A4, CV-A2 and
CV-A8. Of these, EV-A71 accounts for the largest proportion of cases
with unfavorable clinical outcomes, but the frequency of severe dis-
ease caused by other serotypes has been increasing recently [3, 4].
There are frequent HFMD epidemics in the Asia Pacific region, posing
a significant threat to public health [2, 3, 5].
The exact mechanism of severe HFMD pathogenesis remains to be
fully elucidated. Previous studies suggest that enteroviruses invade
and replicate in the central nervous system, initiating a damaging
inflammatory response. Immunopathological injury also affects the
cardiopulmonary system [5]. There are yet no effective antiviral
drugs targeting HFMD associated enteroviruses, although significant
efforts have been made to understand virus-human host interactions
in order to identify promising candidates [6]. The role of viral load in
the progress of HFMD and development of complications is of signifi-
cance to both clinicians and researchers alike. In an animal model,
faster EV-A71 replication was associated with severe disease [7],
implying that pathology is primarily driven by the virus. However,
the relationship between viral load and clinical disease severity has
been rarely studied in HFMD cases to date. Real-time RT-PCR (reverse
transcription-polymerase chain reaction) has been widely used in
HFMD related studies, amplification cycle threshold (Ct) values of
which have been used to indirectly measure viral load as an indicator
of viral genomic load in other studies [8, 9]. Based on a prospective
clinical study of HFMD cases at a children’s hospital, we conductedthis study to examine the associations of viral load with HFMD sever-
ity as well as other potential factors.
2. Methods
2.1. Study participants
The HFMD patients included in this analysis were recruited in a
clinical study of HFMD at Henan Children’s Hospital, which is a pedi-
atric referral hospital in Zhengzhou of Henan province in central
China. The clinical study has been introduced elsewhere [10]. In brief,
all inpatient HFMD cases admitted to Henan Children’s Hospital from
February 15, 2017 to February 15, 2018 were invited to participate in
the study. Demographics, past medical history, clinical data during
hospitalization and clinical specimens on admission were prospec-
tively collected. A total of 1840 HFMD cases were enrolled into the
study, of whom only those with available RT-PCR Ct values for pan-
enterovirus probes and primers from throat swabs collected on
admission were included in this analysis. Data from patients where
the enterovirus serotype could not be determined, where more than
one serotype of enteroviruses was present, or the total number of
cases infected with a given serotype was less than 20, were excluded
from the analysis.
2.2. Outcome measures
The indicators used to define severe HFMD disease were as fol-
lows: CNS complications, including meningitis, encephalitis, brain-
stem encephalitis, encephalomyelitis, acute flaccid paralysis,
autonomic nervous system (ANS) dysregulation and subsequent
severe cardiopulmonary complications [11]; requirement for sys-
temic corticosteroids or intravenous immunoglobulin (IVIG) during
hospitalization, which are recommended for treatment of HFMD
cases with encephalomyelitis and persistent high fever as well as crit-
ical HFMD cases [12]; admission to the intensive care unit (ICU) and
length of hospital stay (LOS) more than 5 days.
2.3. Collection of throat swabs
Throat swabs were collected from enrolled HFMD cases within
48 h of admission. A standardized technique was used to collect the
throat swabs. Throat swab collection was conducted by nurses, who
were specially trained for this task by study staff beforehand. The lat-
eral and posterior pharynx were swabbed two or three times without
touching the tongue or buccal mucosa using a plastic shaft fiber swab
with the aid of a tongue depressor and then the collected swab was
immediately inserted into the conical tube with 3.5 mL of universal
viral transport medium (UTM, Yocon, Beijing, China). All throat swabs
were stored in the 4 °C refrigerator temporarily (no more than 24 h)
before being preserved at 80 °C.
2.4. Virologic assay
RNA extractions and subsequent real-time RT-PCR were com-
pleted by two dedicated laboratory staff who were trained especially
for this study at the Fudan University biosafety level 2 laboratory
(Shanghai, China). Details of the RT-PCR assay have been described
previously [10]. Briefly, RNA was extracted from specimens using
QIAamp Viral RNA Mini Kit (QIAGEN, Hilden, Germany, Cat.#52906)
and tested using real-time RT-PCR with primers for EV-A71, CV-A16
and pan-enterovirus (Quant one step qRT-PCR kit, Tiangen, China,
Cat.#FP30401), if EV-A71 or CV-A16 could not be identified, then
further tested for specific enterovirus serotypes using several nested
RT-PCRs. For nested RT-PCRs, the first-round amplification was per-
formed in a 50 mL reaction volume using a SuperScript III One-Step
RT-PCR Kit (Invitrogen, Carlsbad, CA, USA, Cat.#12574035), and the
C. Song et al. / EBioMedicine 62 (2020) 103078 3second round using DreamTaq Green PCR Master Mix (Invitrogen,
Carlsbad, CA, USA, Cat.#K1082) in a 25 mL volume. The sequences
obtained in this study were submitted to NCBI under accession num-
bers MW028180 - MW029376.
Each operation step, including preprocessing specimens, extract-
ing RNA and amplifying RNA, was performed in different areas of the
laboratory, to avoid false positive testing results. Enterovirus genomic
load was measured using the number of amplification cycles, i.e. Ct
value, required to produce a positive result in real-time RT-PCR. A Ct
value of 38 under "S" melt curve was considered positive. In this
analysis, Ct values of pan-enteroviruses probes and primers in real-
time RT-PCR were used as a semiquantitative proxy for the inverse of
relative viral genomic loads, as in other similar studies [8, 9].2.5. Precision of Ct values and standard curves between relative viral
genomic load and Ct values
Positive and negative controls were in place when extracting and
amplifying RNA in our in-house laboratory system for the real-time
RT-PCR. Across the whole testing period of the study, Ct values of the
positive reagent control were highly reliable, mean § SD (n = 34) of
which were 9.09§0.77 for pan-enterovirus. The reliability of real-
time RT-PCR lays the foundation for using Ct values as proxy of rela-
tive viral genomic load. In order to verify the association between Ct
values and relative viral concentrations, we performed the real-time
RT-PCR under the same conditions on serially diluted samples, which
were collected from three patients and were 2-fold serially diluted
with duplicate wells for each dilution. The Ct values for pan-enterovi-
ruses probes and primers were shown to be positively linearly associ-
ated with the virus concentrations. Based on the standard curves
produced by experiments, the relative genomic concentrations (Crel,
in arbitrary units) could be estimated with Ct values using the follow-
ing formulas: log(Crel)=0.311 £ Ct (Supplementary Fig. 1).2.6. Statistical analyses
The associations between two categorical variables were tested
using chi-square tests and Fisher’s exact tests. The associations
between enterovirus genomic load in Ct values and binary variables
were analysed using Wilcoxon rank-sum test. The associations
between each serotype of enterovirus genomic load in Ct values and
throat swab collection time after illness were analysed using the lin-
ear regression model. Each enterovirus serotype of HFMD cases were
divided into three categories of viral genomic load (low, medium,
high) according to Ct values which were classified into tertiles for
each virus serotype, and associations between four binary clinical
severity outcomes and viral genomic load categories were analysed
using Cochran-Armitage Trend Test.
Logistic regression models were used to calculate the adjusted
odds ratio (OR) of clinically more severe outcomes among viral geno-
mic load categories (low, medium, high), controlling for age, resi-
dence type and parents’ highest education. These three factors were
selected based on biological plausibility and their associations with
both clinical severity and viral genomic load. Systemic corticosteroids
treatment before throat swab collections, which might possibly
increase the viral load of EV-A71 according to an animal study [13],
was not included as a confounding factor in the logistic regression
models for primary analysis, because our analyses demonstrated
there was no association between systemic corticosteroids use before
throat swab collection and viral load among clinically mild HFMD
cases (Supplementary Table 1). In a sensitivity analysis, systemic cor-
ticosteroids use before throat swab collection and throat swab collec-
tion time respectively were added into the regression model to
examine whether there was any major influence on the association
between viral genomic load and clinical severity.Given that it is possible that viral shedding in throat swabs might
have stopped when viral shedding still continues in stool for some
HFMD cases [14], who were actually laboratory confirmed HFMD
cases but were excluded from this study for negative enterovirus
testing results of throat swabs, the sensitivity analysis was performed
by taking into account the virological testing results of stool at the
hospital laboratory, where testing details were described previously
and only two specific virus serotypes (EV-A71 and CV-A16) could be
distinguished [10]. Those participants whose throat swabs tested
negative for enteroviruses but whose stool tested positive for EV-A71
or CV-A16 were added into the analysis as HFMD cases infected with
EV-A71 or CV-A16 and their Ct values were assigned 39, in order to
examine whether there were any significant changes in the associa-
tions between enterovirus genomic load and throat swab collection
time, clinical severity and other factors. All statistical tests were two-
sided and p values  0.05 were considered statistically significant. R
version 3.6.1 was used for all analyses.
2.7. Ethics
The study protocol was reviewed by the Institutional Review
Boards of Henan Children’s Hospital (IRB#YZ-17-006), Chinese center
for Disease Prevention and Control (IRB#201624), and Public Health
School of Fudan University (IRB#2017-12-0654). Written informed
consent was provided by parents or legal guardians of study partici-
pants on enrollment.
2.8. Role of the funding sources
The funders of the study had no role in study design, data collec-
tion, data analysis, interpretation, or writing of the report.
3. Results
During the study period, 1840 children were hospitalised with a
clinical diagnosis of HFMD. Of these, 1109 had throat swabs available
for diagnostic testing, tested positive for a specific enterovirus sero-
type, and were included in this study (Fig. 1). Less than 5% of included
children had underlying medical conditions or low birth weight,
while less than 10% of the study children were had premature births
regardless of enterovirus serotypes, and no patient had an underlying
medical condition causing immunocompromise (Table 1). Forty-two
percent of patients testing positive for EV-A71 were less than 2 years
of age; for the other serotypes more than half of patients were less
than 2 years. The proportion of patients needing ICU admission was
less than 5% for all serotypes apart from EV-A71, whereas the propor-
tion of patients with CNS complications, requiring systemic cortico-
steroids or IVIG, or with length of stay > 5 days (the other three
markers of severe disease) was generally larger than 5% for all sero-
types. The participants included in the analysis were slightly older
and more likely to reside in rural areas than those who were
excluded from analysis. Other demographic characteristics, past
medical history and clinical severity were similar (Supplementary
Table 2).
Viral load appeared to decline with increasing time between ill-
ness onset and throat swab collection for all six serotypes (Fig. 2).
This association was statistically significant for CV-A6, CV-A10 and
CV-A4, but was not significant for EV-A71, CV-A16 and CV-A2 in the
primary analysis (Supplementary Table 3). However, in the sensitivity
analysis accounting for those whose throat swabs were negative but
stools tested positive for EV-A71 or CV-A16, viral genomic loads of
both EV-A71 and CV-A16 still appeared to decline as time increased
between illness onset and throat swab collection (Supplementary Fig.
2), while the slope of decline for these serotypes became statistically
significant (Supplementary Table 3). Importantly, the timing of throat
swab collection after illness onset was similar across different clinical
Fig. 1. Flow diagram of including HFMD inpatient cases in the study.
4 C. Song et al. / EBioMedicine 62 (2020) 103078severities within each serotype (Supplementary Table 4). Children
who were normal birthweight, who resided in urban area and whose
parents received higher education appeared to have slightly higher
viral genomic loads across all six serotypes, but most of these differ-
ences were not statistically significant (Table 2). In the sensitivity
analysis accounting for those whose throat swabs were negative but
stools tested positive for EV-A71 or CV-A16, the results were similar
to those of the primary analyses (Supplementary Table 5).
There was a trend for the risks of all four clinically severe out-
comes to increase with the increase in EV-A71 genomic load catego-
ries (Fig. 3). The associations were statistically significant for risks of
diagnoses of CNS complications (p = 0.016, Cochran-Armitage Trend
Test), the need for systemic corticosteroids or IVIG (p = 0.011,
Cochran-Armitage Trend Test), ICU admission (p = 0.002, Cochran-
Armitage Trend Test) and LOS over 5 days (p = 0.048, Cochran-Armit-
age Trend Test). The similar statistically significant associations also
existed for HFMD cases infected with CV-A6 between viral genomicload and the need for systemic corticosteroids or IVIG (p = 0.024,
Cochran-Armitage Trend Test). No similar trends were found
between the risks of clinically severe outcomes and viral genomic
load categories among HFMD cases infected with CV-A16, CV-10, CV-
A4 or CV-A2, and their associations were not statistically significant
(Supplementary Fig. 3).
In the multivariate analyses adjusting for age, residence type and
parents’ highest education, there was a trend for point estimates of
adjusted ORs to increase with viral genomic load categories for all
four markers of severe disease in children infected with EV-A71. The
associations between relative high viral genomic load and risks of
severe diseases were statistically significant in children with EV-A71
for all four markers of severe disease (Table 3). Similarly, an increased
need for systemic corticosteroids or IVIG in those with higher viral
genomic load remained after adjustment in patients infected with
CV-A6; adjusted ORs for ICU admission could not be calculated
because no cases in low genomic load category were admitted to ICU.
Table 1














Age, years 2.2 (1.53.4) 1.4 (1.1- 2.3) 1.8 (1.42.7) 1.6 (1.22.3) 1.7 (1.32.7) 1.5 (1.22.3) <0.001
Age group
01 years 65 (42) 375 (70) 130 (56) 53 (68) 39 (66) 31 (66) <0.001
214 years 91 (58) 163 (30) 101 (44) 25 (32) 20 (34) 16 (34)
Male 100 (64) 332 (62) 156 (68) 50 (64) 40 (68) 34 (72) 0.51
Rural residence 59 (38) 140 (26) 81 (35) 30 (38) 18 (31) 5 (11) <0.001
Parents’ education
High School or below 76 (49) 190 (35) 93 (40) 31 (40) 25 (42) 11 (23) 0.013
Junior College or above 80 (51) 348 (65) 138 (60) 47 (60) 34 (58) 36 (77)
Underlying medical conditions* 5 (3) 7 (1) 3 (1) 2 (3) 2 (3) 0 (0) 0.33
Premature birthy 7 (4) 18 (3) 14 (6) 6 (8) 2 (3) 4 (9) 0.25
Low birthweightz 6 (4) 15 (3) 9 (4) 3 (4) 2 (3) 1 (2) 0.95
Major feeding ways within 6 months after birth
Breast feeding 115 (74) 383 (71) 171 (74) 52 (67) 44 (75) 35 (74) 0.81
Non-breast feeding 41 (26) 155 (29) 60 (26) 26 (33) 15 (25) 12 (26)
Diagnosed as CNS complications 63 (40) 38 (7) 8 (3) 8 (10) 10 (17) 6 (13) <0.001
Require special treatmentx 74 (47) 52 (10) 15 (6) 8 (10) 11 (19) 6 (13) <0.001
ICU admission 32 (21) 7 (1) 2 (1) 3 (4) 2 (3) 0 (0) <0.001
LOS>5 days 68 (44) 79 (15) 26 (11) 13 (17) 12 (20) 5 (11) <0.001
Data were n (%) or median (IQR). Abbreviations: CNS, central nervous system; ICU, intensive care unit; LOS, length of stay. P-values were estimated by Fisher’s exact
test (ICU admission, underlying medical conditions, premature birth and low birthweight), chi-squared tests (all other categorical characteristics) and Wilcoxon rank-
sum test (age).
* Underlying medical conditions included epilepsy (4), brain damage (3), rickets (3), adenoids hypertrophy (3), delayed milestone (2), cranial nerve injury (1), pro-
gressive muscular dystrophy (1), tuberous sclerosis (1) and fused kidney (1).
y Defined as born before 37 weeks of gestation.
z Defined as birth weight which was below 2500 g.
x Defined as receiving systemic corticosteroids or IVIG during hospitalization.
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severe disease and viral genomic load for CV-A16, CV-A10, CV-A4
and CV-A2 (Supplementary Table 6).
In the sensitivity analysis which included time interval between
illness onset and specimen collection in the multivariate regressionFig. 2. The association between virus genomic load and throat swab collection time since il
CV-A4. (f) CV-A2.
The line represented the linear regression line and the dashed line represented 95% confi
The gray dotted line denoted the threshold of Ct value for determining positive in real time Rmodel, adjusted ORs between relative genomic load groups and risks
of severe HFMD cases changed only slightly compared with the find-
ings for EV-A71 and CV-A6 in the primary analysis (Supplementary
Table 7). In the sensitivity analysis which included systemic cortico-
steroids use before specimen collection into the multivariatelness onset by enterovirus serotype. (a) EV-A71. (b) CV-A6. (c) CV-A16. (d) CV-A10. (e)
dence interval. Lower cycle threshold (Ct) values indicated higher virus genomic loads.
T-PCR.
Table 2
Viral genomic load (Ct values) of throat swabs by characteristic by enterovirus serotype.














01 years 31 (2736) 29 (2633) 29 (2733) 29 (2632) 28 (2536) 29 (2632)
214 years 30 (2737) 29 (2533) 28 (2631) 26 (2429) 30 (2534) 29 (2732)
P value 0.54 0.73 0.053 0.023 0.75 0.78
Sex
Male 30 (2735) 29 (2633) 28 (2632) 28 (2530) 28 (2539) 29 (2633)
Female 31 (2739) 29 (2633) 29 (2635) 28 (2630) 29 (2433) 29 (2631)
P value 0.13 0.56 0.21 0.85 0.76 0.80
Residence type
Rural 32 (2939) 29 (2633) 30 (2735) 27 (2529) 29 (2539) 33 (2934)
Urban 30 (2635) 29 (2633) 28 (2631) 29 (2531) 28 (2532) 29 (2631)
P value 0.023 0.76 0.025 0.21 0.19 0.30
Parents’ highest education
High school or below 31 (2837) 29 (2633) 29 (2634) 28 (2532) 30 (2633) 31 (2834)
Junior college or above 30 (2736) 29 (2633) 28 (2631) 28 (2430) 28 (2537) 29 (2632)
P value 0.24 0.54 0.37 0.37 0.49 0.37
Underlying medical conditions
No 31 (2737) 29 (2633) 29 (2632) 28 (2531) 29 (2539) 29 (2632)
Yes 30 (2935) 31 (3136) 32 (2935) 26 (2428) 26 (2527) . . .
P value 0.87 0.17 0.57 0.68 0.48 . . .
Premature birth*
No 30 (2737) 29 (2633) 28 (2632) 28 (2531) 28 (2533) 29 (2632)
Yes 31 (2632) 31 (2738) 30 (2834) 29 (2729) 34 (3237) 30 (2733)
P value 0.38 0.064 0.13 0.61 0.31 0.88
Low birthweighty
No 30 (2737) 29 (2633) 29 (2632) 28 (2530) 28 (2533) 29 (2632)
Yes 31 (2834) 32 (2939) 29 (2830) 29 (2634) 34 (3237) 31 (3131)
P value 0.78 0.024 0.62 0.66 0.31 0.61
Major feeding ways within 6 months after birth
Non-breast feeding 30 (2634) 28 (2632) 29 (2733) 29 (2530) 28 (2431) 31 (2832)
Breastfeeding 31 (2737) 29 (2634) 28 (2632) 27 (2430) 28 (2539) 29 (2632)
P value 0.30 0.075 0.16 0.39 0.49 0.34
Data were median (IQR). P-values were estimated by Wilcoxon rank-sum test. Abbreviations: Ct, cycle threshold; IQR, interquartile range.
* Defined as born before 37 weeks of gestation.
y Defined as birth weight which was below 2500 g.
Fig. 3. Genomic load categories and risks of four clinically more severe outcomes among HFMD cases by enterovirus serotype. (a) EV-A71. (b) CV-A6.
The point indicated risks of clinically more severe outcomes and the line indicated the 95% confidence interval. The one and two red stars indicated p values less than 0.05 and
0.01, respectively, using Cochran-Armitage Trend Test. Genomic load categories of EV-A71 were classified based on Ct values as follows: low, 34.4; medium, 28.334.3; and high,
<28.3. Genomic load categories of CV-A6 were classified based on Ct values as follows: low,31.2; medium, 26.731.1; and high, <26.7.
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Table 3





Adjusted ORy P value Adjusted ORy P value
Diagnoses as CNS complications
Low Reference . . . Reference . . .
Medium 2.16 (0.934.99) 0.07 0.61 (0.251.46) 0.27
High 3.42 (1.448.12) 0.005 1.06 (0.492.28) 0.89
Require special treatmentz
Low Reference . . . Reference . . .
Medium 2.23 (1.004.99) 0.05 2.50 (1.115.64) 0.03
High 3.27 (1.427.51) 0.005 2.59 (1.165.81) 0.02
ICU admission
Low Reference . . . Reference . . .
Medium 3.26 (0.9511.20) 0.06 NAx NAx
High 7.73 (2.2526.53) 0.001 NAx NAx
LOS over 5 days
Low Reference . . . Reference . . .
Medium 1.37 (0.613.07) 0.44 0.84 (0.451.56) 0.58
High 2.57 (1.135.84) 0.02 1.36 (0.772.40) 0.29
Abbreviations: Ct, cycle threshold; OR, odds ratio; CNS, central nervous system; ICU, intensive care
unit; LOS, length of stay.
* Genomic load categories of EV-A71 were classified based on Ct values as follows: low,34.4;
medium, 28.334.3; and high, <28.3. Genomic load categories of CV-A6 were classified based on Ct
values as follows: low,31.2; medium, 26.731.1; and high, <26.7.
y Odds ratio adjusted for age, residence type and parents’ highest education.
z Defined as receiving systemic corticosteroids or IVIG during hospitalization.
x No case of low genomic load admitted to ICU, thus no reliable model could be established.
C. Song et al. / EBioMedicine 62 (2020) 103078 7regression model, the association between high viral genomic load
groups and increased risks of severe HFMD cases remained for EV-
A71, similar to the findings of the primary analyses (Supplementary
Table 8), but the association between viral genomic group and need
for special treatment was no longer significant for CV-A6. In the sen-
sitivity analyses for HFMD cases infected with EV-A71 and CV-A16,
the increasing risks of clinically severe disease with higher viral
genomic load remained for EV-A71, but were still not observed for
CV-A16 (Supplementary Fig. 4. and Supplementary Table 9), similar
to the findings of the primary analyses.
4. Discussion
In this hospital-based prospective study, we observed that four
markers of disease severity (CNS complications, the need for systemic
corticosteroids or IVIG, admission to ICU and LOS over 5 days) were
more frequent in patients infected with EV-A71 with higher viral
genomic load (as measured by RT-PCR cycle threshold). Similarly, the
need for systemic corticosteroids or IVIG treatment also appeared to
increase with the increase in viral genomic loads of CV-A6, but the
association was not as consistent as for EV-A71 in a sensitivity analy-
sis. We also observed that viral genomic loads of HFMD associated
enteroviruses, including not only the predominant serotypes of CV-
A6 and CV-A10, but also the relatively rare serotype of CV-A4, tended
to decline over time after illness onset. This is the one of the few stud-
ies to examine associations between enterovirus genomic loads and
clinical severities among HFMD cases.
The current evidence suggests that enteroviruses initially repli-
cate in the oropharyngeal cavity and small bowel and then cause a
mild viremia. Thereafter, enteroviruses disseminate to, and replicate
in, other organs and mucous membranes, causing evident clinical ill-
ness [5]. A minority of HFMD cases may develop CNS complications;
in the cases spread of the virus into the CNS is presumed to occur.
The exact route of viral invasion into CNS is unclear but likely
involves the movement of enteroviruses along cranial and peripheral
nerves toward CNS [15, 16]. Tonsils are an important site outside the
CNS for viral replication in HFMD [17], thus viral genomic load in
throat swabs theoretically correlates with viral burden. In animal
models, EV-A71 viral load is lower in surviving animals [18, 19].Therefore, we hypothesised that increasing viral load measured in
throat swabs would correlate with the clinical severity of HFMD. Our
findings confirm this association between viral load and clinical
severity for EV-A71. Given severe HFMD patients may have long term
sequelae [20], it would be interesting to examine the association
between viral load in the acute phase and risk of long term sequelae.
In this study we used four indicators to measure the clinical sever-
ity of HFMD, but these four indicators may differ in their relationship
with disease severity. For instance, the LOS can be affected by factors
other than illness severity [21, 22]. Nevertheless, HFMD cases with
more severe illness generally tended to have a significantly longer
LOS than those patients with milder illness, as observed in another
multi-center study recruiting 466 HFMD patients in Vietnam [23].
The findings that viral genomic load was associated with all four indi-
cators of clinical severity for EV-A71 increased our confidence in the
validity of the association. However, these findings are inconsistent
with several other Chinese studies which failed to detect statistically
significant differences, although clinically severe cases often showed
a trend towards higher viral load [24]. Our study is the largest to
date, therefore previous findings may be explained by insufficient
sample size, or a lack of adequate assessment of the impact of speci-
men collection time.
In our study, the association of viral genomic loads with disease
severity was only significant for EV-A71, and was not consistently sta-
tistically significant for other enterovirus serotypes. This was likely due
to insufficient sample size; the case numbers for CV-A10, CV-4 and CV-
A2 were all less than 100. On the other hand, clinically severe disease
was rare for CV-A6 and CV-A16, despite the large number of cases
observed for this serotype. Alternatively, it is possible other non-EV-
A71 enteroviruses might have exhibited a different disease mechanism;
most past pathological studies focused on EV-A71 and have rarely stud-
ied other serotypes. Therefore, clinico-pathological studies of non-EV-
A71 enteroviruses with larger sample sizes are warranted in the future,
and are particularly important given that monovalent EV-A71 vaccine
is available and effective in real world use [10].
Our study findings demonstrated viral load appeared to decline
over time after illness onset for all the six serotypes; however, this
association was statistically significant for CV-A6, CV-A10 and CV-A4,
but was not significant for EV-A71, CV-A16 and CV-A2 in the primary
8 C. Song et al. / EBioMedicine 62 (2020) 103078analysis. Failure to detect a significant association between viral
genomic load and throat swab collection time might be attributed to
the exclusion of those whose viral shedding had stopped at the early
phase of illness or relatively small sample size. Therefore, in the sen-
sitivity analysis, we added the study subjects whose throat swabs
tested negative for enteroviruses but whose stool tested positive for
EV-A71 or CV-A16 back into the analysis, allowing us to detect a sta-
tistically significant difference. The comparison of point estimates of
rate of decline between virus serotypes in the primary analysis sug-
gested that viral load of EV-A71 and CV-A16 may decline more slowly
than other serotypes CV-A6. This is consistent with the results of pre-
vious viral shedding studies, which indicated that shedding of EV-
A71 and CV-A16 declined relatively more slowly than CV-A6 [25, 26],
increasing confidence in our findings.
This is a comprehensive study on the association of viral load with
HFMD severity as well as other potential factors, but several limitations
need to be noted. Firstly, viral load was not measured using typical pla-
que assay or quantitative RT-PCR but quantified with relative viral
genomic load based on Ct values as proxy instead. Nevertheless, our
laboratory data confirmed the stability of our in-house assay system
and linear associations between Ct values and RNA concentrations,
which enhanced the robustness of quantifying relative viral genomic
load based on Ct values. Moreover, in our study throat swabs were col-
lected following a standardized quantitative protocol and collection
operations were performed by well trained and qualified study nurses,
which minimized the variability of viral genomic load attributed to
specimen collections and thus lent us more confidence that viral geno-
mic load measured in our laboratory reflected that in patients. Sec-
ondly, although our study showed viral genomic load appeared to
decrease in throat swabs over time after illness onset, throat swabs
were only collected at a single time point per patient, rather than at
multiple time points. The dynamics of viral genomic loads need to be
further explored in longitudinal studies. Thirdly, given our study sub-
jects were hospitalised HFMD cases, and HFMD cases included in the
analysis were slightly older and more likely to reside in rural areas
than those who were excluded, our study findings may not necessarily
apply to outpatient HFMD cases, community cases or other more gen-
eral population. Nevertheless, the priority of HFMD management
focuses on clinical severe cases, therefore our findings are of significant
clinical relevance. Finally, our study was conducted at a single hospital.
In future, similar studies should be conducted in multiple hospitals to
verify the generalisability of our findings.
In conclusion, our study confirms that the severity of HFMD is corre-
lated with viral genomic loads of EV-A71 in throat swabs. Such associa-
tions might exist for CV-A6, and need to be verified in another study
with a larger number of CV-A6 cases. Viral genomic load in throat
swabs might be negatively associated with time of specimen collection
after illness onset for laboratory confirmed HFMD cases. Specific antivi-
ral drugs should be developed to reduce enterovirus load, such meas-
ures would be expected to reduce the clinical severity of HFMD.
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